The results showed that METTL3 was highly expressed in 17 tumors including bladder urothelial carcinoma (BLCA), extrahepatic cholangiocarcinoma (CHOL) and colon adenocarcinoma (COAD). This evidence concerns the gene METTL3 and bladder transitional cell carcinoma.